209 related articles for article (PubMed ID: 37336826)
21. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.
Makker V; Rasco D; Vogelzang NJ; Brose MS; Cohn AL; Mier J; Di Simone C; Hyman DM; Stepan DE; Dutcus CE; Schmidt EV; Guo M; Sachdev P; Shumaker R; Aghajanian C; Taylor M
Lancet Oncol; 2019 May; 20(5):711-718. PubMed ID: 30922731
[TBL] [Abstract][Full Text] [Related]
22. Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients.
Yang X; Chen B; Wang Y; Wang Y; Long J; Zhang N; Xue J; Xun Z; Zhang L; Cheng J; Lei J; Sun H; Li Y; Lin J; Xie F; Wang D; Pan J; Hu K; Guan M; Huo L; Shi J; Yu L; Zhou L; Zhou J; Lu Z; Yang X; Mao Y; Sang X; Lu Y; Zhao H
Hepatol Int; 2023 Jun; 17(3):709-719. PubMed ID: 36753026
[TBL] [Abstract][Full Text] [Related]
23. A retrospective cohort study of sintilimab and pembrolizumab as first-line treatments for advanced non-small cell lung cancer.
Wu K; Fu Y; Zeng D; Chen T; Wang C; Jiang J
J Thorac Dis; 2022 Mar; 14(3):679-688. PubMed ID: 35399230
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the efficacy and safety in the treatment strategies between chemotherapy combined with antiangiogenic and with immune checkpoint inhibitors in advanced non-small cell lung cancer patients with negative PD-L1 expression: A network meta-analysis.
Li J; Chen Y; Hu F; Qiang H; Chang Q; Qian J; Shen Y; Cai Y; Chu T
Front Oncol; 2022; 12():1001503. PubMed ID: 36523992
[TBL] [Abstract][Full Text] [Related]
25. Correlation of HBV DNA and Hepatitis B Surface Antigen Levels With Tumor Response, Liver Function and Immunological Indicators in Liver Cancer Patients With HBV Infection Undergoing PD-1 Inhibition Combinational Therapy.
Pan S; Yu Y; Wang S; Tu B; Shen Y; Qiu Q; Liu X; Su N; Zuo Y; Luan J; Zhang JY; Shi M; Meng F; Wang FS
Front Immunol; 2022; 13():892618. PubMed ID: 35711409
[TBL] [Abstract][Full Text] [Related]
26. Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study.
Chen S; Wu Z; Shi F; Mai Q; Wang L; Wang F; Zhuang W; Chen X; Chen H; Xu B; Lai J; Guo W
J Cancer Res Clin Oncol; 2022 Aug; 148(8):2115-2125. PubMed ID: 34453221
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of pembrolizumab versus sintilimab treatment in patients with advanced squamous lung cancer: A real-world study in China.
Yang W; Li T; Bai Y; Long Y; Gao M; Wang T; Jing F; Zhang F; Tao H; Ma J; Wang L; Hu Y
Front Oncol; 2023; 13():1147903. PubMed ID: 37124534
[TBL] [Abstract][Full Text] [Related]
28. Association between PD-1 inhibitor-related adverse events and frailty assessed by frailty index in lung cancer patients.
Li J; Zhang X; Zhou S; Zhou Y; Liu X
Cancer Med; 2023 Apr; 12(8):9272-9281. PubMed ID: 36727563
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non-small cell lung cancer: A sequential model.
Zhao M; Shao T; Chi Z; Tang W
Front Public Health; 2023; 11():1051484. PubMed ID: 36908446
[TBL] [Abstract][Full Text] [Related]
30. Lenvatinib Combined with the PD-1 Inhibitor Camrelizumab in the Treatment of Primary Liver Cancer Caused Hemorrhagic Exfoliative Gastritis.
Chen H; Wang Z; Wang C
Case Rep Oncol; 2024; 17(1):543-548. PubMed ID: 38595961
[TBL] [Abstract][Full Text] [Related]
31. Triple therapy in biliary tract cancers: GemOX plus immune checkpoint inhibitor in combination with lenvatinib or NGS-guided targeted therapy.
Dong X; Zhang Z; Zhang Q; Chen L; Cao G; Liu C; Song T; Lu W; Zhang W
J Cancer Res Clin Oncol; 2023 May; 149(5):1917-1927. PubMed ID: 35802197
[TBL] [Abstract][Full Text] [Related]
32. Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients.
Song P; Zhang D; Cui X; Zhang L
Thorac Cancer; 2020 Sep; 11(9):2406-2430. PubMed ID: 32643323
[TBL] [Abstract][Full Text] [Related]
33. Adverse events of different PD-1 inhibitors in lung cancer patients: a real-world study.
Zheng X; Tao G; Sun S; Jin X; Chen Y; Zhang Y; Sun J; Huang P
Ann Transl Med; 2022 Feb; 10(4):183. PubMed ID: 35280395
[TBL] [Abstract][Full Text] [Related]
34. Correlation and efficacy of TACE combined with lenvatinib plus PD-1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features.
Zou X; Xu Q; You R; Yin G
Cancer Med; 2023 May; 12(10):11315-11333. PubMed ID: 36951443
[TBL] [Abstract][Full Text] [Related]
35. Experience With Anti-PD-1 Antibody, Camrelizumab, Monotherapy for Biliary Tract Cancer Patients and Literature Review.
Shen T; Zheng S; Geng L; Liu Z; Xu J; Lin B; Qian J; Zheng S
Technol Cancer Res Treat; 2020; 19():1533033820979703. PubMed ID: 33308041
[TBL] [Abstract][Full Text] [Related]
36. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic effectiveness and safety of sintilimab-dominated triple therapy in unresectable hepatocellular carcinoma.
Dai L; Cai X; Mugaanyi J; Liu Y; Mao S; Lu C; Lu C
Sci Rep; 2021 Oct; 11(1):19711. PubMed ID: 34611195
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma.
Zhou T; Wang X; Cao Y; Yang L; Wang Z; Ma A; Li H
BMC Health Serv Res; 2022 Nov; 22(1):1367. PubMed ID: 36397064
[TBL] [Abstract][Full Text] [Related]
39. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
40. Postprogression treatment of lenvatinib plus PD-1 inhibitor in advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy.
An C; Fu Y; Li W; Zuo M; Wu P
Cancer; 2023 Jul; 129(14):2235-2244. PubMed ID: 37029486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
